Citius Oncology (CTOR) Action Cours

Citius Oncology Inc is a biotechnology company based in New York City, United States, operating within the Health Care sector. The company went public via an IPO on October 14, 2022, and its stock trades under the ticker CTOR with ISIN US17331Y1091. Citius Oncology focuses on developing and commercializing targeted oncology therapies, with its lead product candidate named LYMPHIR. LYMPHIR is an engineered IL-2 diphtheria toxin fusion protein designed for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma (CTCL), a rare form of non-Hodgkin lymphoma. The therapy is indicated for use in Stage I-III disease following at least one prior systemic therapy. LYMPHIR functions as a targeted immune therapy that combines the IL-2 receptor binding domain with diphtheria toxin fragments. It specifically binds to IL-2 receptors on the surface of cancer cells, leading to the internalization of diphtheria toxin fragments. Once inside the cell, the diphtheria toxin is cleaved, and the free fragments inhibit protein synthesis, ultimately causing cell death. The company’s website is citiusonc.com, and it is engaged in the development of innovative treatments for rare oncology conditions. Citius Oncology does not disclose additional product candidates or clinical trial details beyond the information provided in the source material. The company’s operations and focus remain centered on advancing LYMPHIR through the development and commercialization process.